Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05929755 · ClinicalTrials.gov registry record · Phase 4

Depo-Medrol on Psoas After LLIF

A Phase 4 study of Pain, Postoperative and Muscle Weakness, sponsored by Hardeep Singh.

Recruiting
Registry status
Phase 4
Development phase
80
Enrollment target
1
Study location

NCT05929755 is a Phase 4 study of Pain, Postoperative and Muscle Weakness that is actively recruiting participants, run by Hardeep Singh. The registered enrollment target is 80 participants, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05929755, a Phase 4 study of Pain, Postoperative and Muscle Weakness, is actively recruiting participants, sponsored by Hardeep Singh.

RECRUITING
Registry status
Phase 4
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

Interventions

  • DRUG Depo-Medrol
  • DRUG Gel-Flow NT

Study Locations (1)

Connecticut

  • UConn Health - Farmington

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-05-12
Est. Completion 2027-05
Phase Phase 4

Sponsor

Hardeep Singh

1 total trials

What the Registry Record Tells You About NCT05929755

The ClinicalTrials.gov registry entry for NCT05929755 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (71% lower). The listed sponsor is Hardeep Singh, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Pain, Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Depo-Medrol is the first listed.

NCT05929755 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05929755 about?

NCT05929755 is a clinical study titled "Depo-Medrol on Psoas After LLIF". The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

What is the current status of trial NCT05929755?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-05-12. Estimated completion is 2027-05.

What conditions does trial NCT05929755 study?

This clinical trial studies the following conditions: Pain, Postoperative, Muscle Weakness, Paresthesia, Pain, Muscle.

What interventions are being tested in trial NCT05929755?

The interventions under investigation include: Depo-Medrol (DRUG), Gel-Flow NT (DRUG).

Who is sponsoring clinical trial NCT05929755?

This trial is sponsored by Hardeep Singh, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05929755 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.